Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2 diabetes was demonstrated in the LEADER (ClinicalTrials.gov: NCT01179048) and SUSTAIN 6 (ClinicalTrials.gov: NCT01720446) cardiovascular outcome trials. This post hoc analysis assessed the impact of diabetes durat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Obes Metab
Auteurs principaux: Verma, Subodh, Bain, Stephen C., Monk Fries, Tea, Mazer, C. David, Nauck, Michael A., Pratley, Richard E., Rasmussen, Søren, Saevereid, Hans A., Zinman, Bernard, Buse, John B.
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2019
Sujets:
Brief Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6619033/
https://ncbi.nlm.nih.gov/pubmed/30851070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13698
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires